U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent T-Cell Non-Hodgkin Lymphoma

MedGen UID:
163467
•Concept ID:
C0854826
•
Neoplastic Process
Synonyms: Recurrent T-Cell and NK-Cell Non-Hodgkin's Lymphoma; Recurrent T-Cell Lymphoma; Recurrent T-Cell Non-Hodgkin's Lymphoma; Relapsed T-Cell Lymphoma; T-Cell Lymphoma Recurrent; T-Cell Lymphoma Relapsed

Definition

The reemergence of T-cell non-Hodgkin lymphoma after a period of remission. [from NCI]

Professional guidelines

PubMed

Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD, Baehring JM
Curr Treat Options Oncol 2022 Nov;23(11):1548-1565. Epub 2022 Oct 7 doi: 10.1007/s11864-022-01016-5. PMID: 36205806
AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review.
Green PHR, Paski S, Ko CW, Rubio-Tapia A
Gastroenterology 2022 Nov;163(5):1461-1469. Epub 2022 Sep 19 doi: 10.1053/j.gastro.2022.07.086. PMID: 36137844
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
Susanibar-Adaniya S, Barta SK
Am J Hematol 2021 May 1;96(5):617-629. Epub 2021 Mar 19 doi: 10.1002/ajh.26151. PMID: 33661537Free PMC Article

Recent clinical studies

Etiology

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, Morschhauser F, Alpdogan O, Suh C, Tobinai K, Shustov A, Trneny M, Yuen S, Zinzani PL, Trümper L, Ilidge T, O'Connor OA, Pro B, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Iyer S
Blood Adv 2022 Oct 11;6(19):5550-5555. doi: 10.1182/bloodadvances.2020003971. PMID: 35470385Free PMC Article
Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis.
Du J, Yu D, Han X, Zhu L, Huang Z
JAMA Netw Open 2021 May 3;4(5):e219807. doi: 10.1001/jamanetworkopen.2021.9807. PMID: 34042995Free PMC Article
Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P, Zhang M
Clin Epigenetics 2020 Nov 7;12(1):169. doi: 10.1186/s13148-020-00962-x. PMID: 33160401Free PMC Article
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators
Lancet Oncol 2018 Sep;19(9):1192-1204. Epub 2018 Aug 9 doi: 10.1016/S1470-2045(18)30379-6. PMID: 30100375
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S
J Clin Oncol 2011 Mar 20;29(9):1182-9. Epub 2011 Jan 18 doi: 10.1200/JCO.2010.29.9024. PMID: 21245435Free PMC Article

Diagnosis

Cutaneous T-cell lymphoma: diagnosing subtypes and the challenges.
Hague C, Farquharson N, Menasce L, Parry E, Cowan R
Br J Hosp Med (Lond) 2022 Apr 2;83(4):1-7. Epub 2022 Apr 14 doi: 10.12968/hmed.2021.0149. PMID: 35506718
How I Diagnose Angioimmunoblastic T-Cell Lymphoma.
Xie Y, Jaffe ES
Am J Clin Pathol 2021 Jun 17;156(1):1-14. doi: 10.1093/ajcp/aqab090. PMID: 34117736Free PMC Article
Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P, Zhang M
Clin Epigenetics 2020 Nov 7;12(1):169. doi: 10.1186/s13148-020-00962-x. PMID: 33160401Free PMC Article
Adult-Onset Atopic Dermatitis.
Silverberg JI
J Allergy Clin Immunol Pract 2019 Jan;7(1):28-33. doi: 10.1016/j.jaip.2018.09.029. PMID: 30598180
NK-Cell Lymphomas.
Chihara D, Oki Y
Cancer Treat Res 2019;176:163-184. doi: 10.1007/978-3-319-99716-2_8. PMID: 30596218

Therapy

Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis.
Du J, Yu D, Han X, Zhu L, Huang Z
JAMA Netw Open 2021 May 3;4(5):e219807. doi: 10.1001/jamanetworkopen.2021.9807. PMID: 34042995Free PMC Article
Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P, Zhang M
Clin Epigenetics 2020 Nov 7;12(1):169. doi: 10.1186/s13148-020-00962-x. PMID: 33160401Free PMC Article
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators
Lancet Oncol 2018 Sep;19(9):1192-1204. Epub 2018 Aug 9 doi: 10.1016/S1470-2045(18)30379-6. PMID: 30100375
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.
Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y
Blood 2014 May 15;123(20):3095-100. Epub 2014 Mar 20 doi: 10.1182/blood-2013-12-542142. PMID: 24652992Free PMC Article
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S
J Clin Oncol 2011 Mar 20;29(9):1182-9. Epub 2011 Jan 18 doi: 10.1200/JCO.2010.29.9024. PMID: 21245435Free PMC Article

Prognosis

PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma.
Wartewig T, Daniels J, Schulz M, Hameister E, Joshi A, Park J, Morrish E, Venkatasubramani AV, Cernilogar FM, van Heijster FHA, Hundshammer C, Schneider H, Konstantinidis F, Gabler JV, Klement C, Kurniawan H, Law C, Lee Y, Choi S, Guitart J, Forne I, Giustinani J, Müschen M, Jain S, Weinstock DM, Rad R, Ortonne N, Schilling F, Schotta G, Imhof A, Brenner D, Choi J, Ruland J
Nat Cancer 2023 Oct;4(10):1508-1525. Epub 2023 Sep 18 doi: 10.1038/s43018-023-00635-7. PMID: 37723306Free PMC Article
Cutaneous T-cell lymphoma: diagnosing subtypes and the challenges.
Hague C, Farquharson N, Menasce L, Parry E, Cowan R
Br J Hosp Med (Lond) 2022 Apr 2;83(4):1-7. Epub 2022 Apr 14 doi: 10.12968/hmed.2021.0149. PMID: 35506718
Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma.
Song X, Chang S, Seminario-Vidal L, de Mingo Pulido A, Tordesillas L, Song X, Reed RA, Harkins A, Whiddon S, Nguyen JV, Segura CM, Zhang C, Yoder S, Sayegh Z, Zhao Y, Messina JL, Harro CM, Zhang X, Conejo-Garcia JR, Berglund A, Sokol L, Zhang J, Rodriguez PC, Mulé JJ, Futreal AP, Tsai KY, Chen PL
Cancer Discov 2022 May 2;12(5):1294-1313. doi: 10.1158/2159-8290.CD-21-1207. PMID: 35247891Free PMC Article
Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P, Zhang M
Clin Epigenetics 2020 Nov 7;12(1):169. doi: 10.1186/s13148-020-00962-x. PMID: 33160401Free PMC Article
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S
J Clin Oncol 2011 Mar 20;29(9):1182-9. Epub 2011 Jan 18 doi: 10.1200/JCO.2010.29.9024. PMID: 21245435Free PMC Article

Clinical prediction guides

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS
Lancet Oncol 2022 Jan;23(1):91-103. Epub 2021 Dec 8 doi: 10.1016/S1470-2045(21)00591-X. PMID: 34895487
Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P, Zhang M
Clin Epigenetics 2020 Nov 7;12(1):169. doi: 10.1186/s13148-020-00962-x. PMID: 33160401Free PMC Article
Acute Lymphoblastic Leukemia in the Older Adult.
Aldoss I, Forman SJ, Pullarkat V
J Oncol Pract 2019 Feb;15(2):67-75. doi: 10.1200/JOP.18.00271. PMID: 30763199
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators
Lancet Oncol 2018 Sep;19(9):1192-1204. Epub 2018 Aug 9 doi: 10.1016/S1470-2045(18)30379-6. PMID: 30100375
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M
N Engl J Med 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919. PMID: 29385376Free PMC Article

Recent systematic reviews

Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data.
Zinzi A, Gaio M, Liguori V, Cagnotta C, Paolino D, Paolisso G, Castaldo G, Nicoletti GF, Rossi F, Capuano A, Rafaniello C
Pharmacol Res 2023 Apr;190:106742. Epub 2023 Mar 22 doi: 10.1016/j.phrs.2023.106742. PMID: 36963592
Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.
Kim J, Cho J, Yoon SE, Kim WS, Kim SJ
Cancer Res Treat 2023 Jul;55(3):1031-1047. Epub 2023 Mar 13 doi: 10.4143/crt.2022.1658. PMID: 36915243Free PMC Article
CAR-T cell therapy for patients with hematological malignancies. A systematic review.
Pasqui DM, Latorraca CDOC, Pacheco RL, Riera R
Eur J Haematol 2022 Dec;109(6):601-618. Epub 2022 Sep 18 doi: 10.1111/ejh.13851. PMID: 36018500
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M
Cochrane Database Syst Rev 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. PMID: 34515338Free PMC Article
Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis.
Du J, Yu D, Han X, Zhu L, Huang Z
JAMA Netw Open 2021 May 3;4(5):e219807. doi: 10.1001/jamanetworkopen.2021.9807. PMID: 34042995Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...